FDA Accepts IND for GRC 54276 in Advanced Solid Tumors and Lymphomas
A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.
FDA Green Lights FTD of RRx-001 to Mitigate Severe Oral Mucositis in Head and Neck Cancers
The FDA has granted a fast-track designation for RRx-001 and accepted the investigational new drug application for a phase 2b trial of severe oral mucositis in chemotherapy- and radiation-treated patients with head & neck cancer.
Researchers Explore Novel Treatment Strategies CNS Lymphoma
In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.
FDA Grants Full Approval to Pembrolizumab for MSI-H and dMMR Solid Tumors
A full approval has been granted to pembrolizumab by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.
Expert Stresses Importance of Transportation Security to Improve Cancer Care
In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.
Atezolizumab Before/Concurrent With CRT Enhances Immunogenicity in Cervical Cancer
At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.
FDA Lifts Partial Hold on Phase 1/2 VELA Trial of BLU-222 for Solid Tumors
As of March 28, 2023, the partial clinical hold on the phase 1/2 VELA trial, which is evaluating the selective CDK2 inhibitor BLU-222 for patients with solid tumors, has been lifted. Blueprint Medicines has resumed the re-initiation of patient enrollment.
Mitigating Toxicities Arising From Combination Therapies in RCC
March 29th 2023Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.
Phase 1 Study of PT886 Doses First Patient With Gastric/GEJ/Pancreatic Cancer
PT886, a novel bispecific antibody which targets claudin 18.2 and CD47, is currently being evaluated in a phase 1 study for patients with gastric, gastroesophageal junction and pancreatic adenocarcinomas.
In 2 MMR Cohorts, Pembrolizumab/Chemotherapy Benefits Survival in Advanced Endometrial Cancer
March 28th 2023In the NRG GY018 trial, the addition of pembrolizumab to standard-of-care chemotherapy followed by maintenance pembrolizumab demonstrated a reduction in risk of disease progression or death in patients with advanced or recurrent endometrial cancer.